Seyed Mohsen Hosseini

Seyed Mohsen Hosseini

Auto-generated profile, based on publicly available information

Seyed Mohsen Hosseini

Ahvaz Jundishapur University of Medical Sciences: Ahvaz Jondishapour University of Medical Sciences

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Informatics in Medicine Unlocked
Verified
Journal Article
Open access
AJAmir Jamshidnezhad
Amir Jamshidnezhad
SHSeyed Mohsen Hosseini
Seyed Mohsen Hosseini
JMJavad Mohammadi-Asl
Javad Mohammadi-Asl
MMMandana Mahmudi
Mandana Mahmudi

6 July 2020 in JMIR Medical Informatics
Verified
Journal Article
Open access
AJAmir Jamshidnezhad
Amir Jamshidnezhad
MZMarzie Zilaee
Marzie Zilaee
BFbehzad fouladi
behzad fouladi
AMAbbas Mohammadi
Abbas Mohammadi
SHSeyed Mohsen Hosseini
Seyed Mohsen Hosseini
Background: Asthma is commonly associated with chronic airway inflammation and is the underlying cause of over a million deaths each year. Crocus sativus L, commonly known as saffron, when used in the form of traditional medicines, has demonstrated anti-inflammatory effects which may be beneficial to individuals with asthma. Objective: The objective of this study was to develop a clinical prediction system using an artificial neural network to detect the effects of C sativus L supplements on patients with allergic asthma. Methods: A genetic algorithm–modified neural network predictor system was developed to detect the level of effectiveness of C sativus L using features extracted from the clinical, immunologic, hematologic, and demographic information of patients with asthma. The study included data from men (n=40) and women (n=40) individuals with mild or moderate allergic asthma from 18 to 65 years of age. The aim of the model was to estimate and predict the level of effect of C sativus L supplements on each asthma risk factor and to predict the level of alleviation in patients with asthma. A genetic algorithm was used to extract input features for the clinical prediction system to improve its predictive performance. Moreover, an optimization model was developed for the artificial neural network component that classifies the patients with asthma using C sativus L supplement therapy. Results: The best overall performance of the clinical prediction system was an accuracy greater than 99% for training and testing data. The genetic algorithm–modified neural network predicted the level of effect with high accuracy for anti–heat shock protein (anti-HSP), high sensitivity C-reactive protein (hs-CRP), forced expiratory volume in the first second of expiration (FEV1), forced vital capacity (FVC), the ratio of FEV1/FVC, and forced expiratory flow (FEF25%-75%) for testing data (anti-HSP: 96.5%; hs-CRP: 98.9%; FEV1: 98.1%; FVC: 97.5%; FEV1/FVC ratio: 97%; and FEF25%-75%: 96.7%, respectively). Conclusions: The clinical prediction system developed in this study was effective in predicting the effect of C sativus L supplements on patients with allergic asthma. This clinical prediction system may help clinicians to identify early on which clinical factors in asthma will improve over the course of treatment and, in doing so, help clinicians to develop effective treatment plans for patients with asthma.

23 October 2020 in Research Square
Verified
Preprint
Open access
PDF file
AJAmir Jamshidnezhad
Amir Jamshidnezhad
SHSeyed Mohsen Hosseini
Seyed Mohsen Hosseini
JMJavad Mohammadi-Asl
Javad Mohammadi-Asl
MMMandana Mahmoudi
Mandana Mahmoudi
Objective: Early and accurate diagnosis of genetic diseases such as Down syndrome can lead to correct action and prevent irreversible events. Therefore, the use of accurate and low-risk diagnostic methods to detect these diseases in the fetal period is important. In this study, a combined artificial neural network (ANN) and genetic algorithm (GA) was used to predict Down syndrome through first trimester screening test. In order to examine the proposed model, sample data were collected on 381 pregnant women who referred to a private screening reference laboratory for the first trimester screening test and NT ultrasound between 11 and 13 weeks of gestation. The proposed model in this study was a feedforward neural which its structure and input parameters were determined by (GA).Results: The average of 10 times experiments showed that the developed model can accurately identify cases of Down syndrome with specificity of 99.72% and sensitivity of 90.91%, and a mean square error (MSE) of 0.61%. The results of this study showed that the use of GA in optimizing the structure of the neural network technique can increase the accuracy in diagnosing Down syndrome through the information of first trimester screening tests.

21 December 2019 in JMIR Preprints
Verified
Preprint
Open access
SHSeyed Ahmad Hosseini
Seyed Ahmad Hosseini
AJAmir Jamshidnezhad
Amir Jamshidnezhad
MZMarzie Zilaee
Marzie Zilaee
BFbehzad fouladi
behzad fouladi
AMAbbas Mohammadi
Abbas Mohammadi
SHSeyed Mohsen Hosseini
Seyed Mohsen Hosseini
BACKGROUND Asthma is commonly associated with chronic airway inflammation and is the underlying cause of over a million deaths each year. Crocus sativus L, commonly known as saffron, when used in the form of traditional medicines, has demonstrated anti-inflammatory effects which may be beneficial to individuals with asthma. OBJECTIVE The objective of this study was to develop a clinical prediction system using an artificial neural network to detect the effects of C sativus L supplements on patients with allergic asthma. METHODS A genetic algorithm–modified neural network predictor system was developed to detect the level of effectiveness of C sativus L using features extracted from the clinical, immunologic, hematologic, and demographic information of patients with asthma. The study included data from men (n=40) and women (n=40) individuals with mild or moderate allergic asthma from 18 to 65 years of age. The aim of the model was to estimate and predict the level of effect of C sativus L supplements on each asthma risk factor and to predict the level of alleviation in patients with asthma. A genetic algorithm was used to extract input features for the clinical prediction system to improve its predictive performance. Moreover, an optimization model was developed for the artificial neural network component that classifies the patients with asthma using C sativus L supplement therapy. RESULTS The best overall performance of the clinical prediction system was an accuracy greater than 99% for training and testing data. The genetic algorithm–modified neural network predicted the level of effect with high accuracy for anti–heat shock protein (anti-HSP), high sensitivity C-reactive protein (hs-CRP), forced expiratory volume in the first second of expiration (FEV1), forced vital capacity (FVC), the ratio of FEV1/FVC, and forced expiratory flow (FEF25%-75%) for testing data (anti-HSP: 96.5%; hs-CRP: 98.9%; FEV1: 98.1%; FVC: 97.5%; FEV1/FVC ratio: 97%; and FEF25%-75%: 96.7%, respectively). CONCLUSIONS The clinical prediction system developed in this study was effective in predicting the effect of C sativus L supplements on patients with allergic asthma. This clinical prediction system may help clinicians to identify early on which clinical factors in asthma will improve over the course of treatment and, in doing so, help clinicians to develop effective treatment plans for patients with asthma.